Investor Confidence Grows in AnaptysBio Victory Capital Management has acquired 97,200 shares of AnaptysBio, reflecting increasing institutional interest. Despite a challenging year with a 52-week low of $12.21, the stock has shown resilience following better-than-expected earnings. Analysts predict a continued "Moderate Buy" outlook, citing potential for long-term growth.34